Estia Health share price on watch after coronavirus update

The Estia Health Ltd (ASX:EHE) share price will be on watch today after withdrawing its guidance due to the coronavirus outbreak…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Estia Health Ltd (ASX: EHE) share price could come under further pressure on Tuesday after it became the latest company to withdraw its guidance for FY 2020.

This follows moves by companies such as Cochlear Limited (ASX: COH) on Monday and Webjet Limited (ASX: WEB) last week that did the same.

What did Estia Health announce?

This morning Estia Health provided an update on current trading and its guidance for the full year.

According to the release, at this point, management notes that none of its homes have experienced cases of COVID-19 among residents or employees nor been materially impacted. As of March 15, the company's occupancy rate within its mature home portfolio was 93.8%.

However, due to the heightened uncertainty surrounding the potential future impact of coronavirus, the company is suspending its FY 2020 guidance.

The company notes that Australia is experiencing an unprecedented public health crisis of unknown dimensions with economic and financial implications that cannot at this point be estimated.

What now?

Management advised that it continues to monitor the COVID-19 situation closely and is planning for any further escalation.

Its focus is on the wellbeing and safety of staff and the frail and vulnerable residents and their families, while at the same time being responsive to the community need for access to residential aged care.

Management said: "At this stage it is not possible to have a high degree of certainty about the impact the situation may have on future occupancy, revenue and costs across the company's 69 homes. Given the dynamic and uncertain nature of this situation, it is not possible to provide meaningful guidance at this time on the size of the projected impact on earnings for the remainder of FY20."

The company notes that its disciplined capital management continues to be a key element of its strategy and its balance sheet strength is expected to give it greater flexibility and depth of resource to meet the challenges the crisis may present.

As of March 13, its net debt stood at ~$106 million, with undrawn and committed facilities under its Syndicated Financing Facility of ~$216 million. The net RAD balance on March 13 was ~$827 million, which includes amounts due under probate.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. and Webjet Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Man looking happy and excited as he looks at his mobile phone.
Healthcare Shares

Guess which ASX healthcare stock is jumping 7% on big news

This stock is getting a lot of attention from investors on Wednesday. But why?

Read more »

Four smiling young medics with arms crossed stand outside a hospital.
Healthcare Shares

How much further upside is there for Mesoblast shares after soaring 23% in a month?

Could FDA approval send this healthcare stock towards further gains?

Read more »

woman in lab coat conducting testing representing biotech
Healthcare Shares

Is this soaring ASX 200 healthcare share just getting started?

If its lead therapy gets US approval, the stock can continue to climb.

Read more »

A happy elderly woman smiles and cheers as she looks at good investment news on her laptop.
Broker Notes

Macquarie forecasts this $3.4 billon ASX healthcare share is set surge 33%

Macquarie tips material outperformance from this ASX healthcare share in 2026.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Own CSL shares? Here are the key dates for 2026

It's been a bad year for CSL shares. What's ahead in 2026?

Read more »

A graphic of a pink rocket taking off above an increasing chart.
Healthcare Shares

Guess which ASX 300 healthcare share is rocketing 28% on global expansion news

Investors are piling into the ASX 300 healthcare share on Tuesday. Let’s see why.

Read more »

A man in a business suit scratches his head looking at a graph that started high then dips, then starts to go up again like a rollercoaster.
Healthcare Shares

Is Sigma Healthcare share a healthy buy, after hitting new lows?

The Chemist Warehouse merger and ageing population might boost this stock's appeal.

Read more »

A sad looking scientist sitting and upset about a share price fall.
Healthcare Shares

Telix shares fall despite 'significant milestone'

Let's see what the biotech has announced on Monday.

Read more »